SR-4835 |
| رقم الكتالوجGC39175 |
يعتبر SR-4835 مثبطًا مزدوجًا قويًا وانتقائيًا للغاية وتنافسي ATP لـ CDK12 / CDK13 (CDK12: IC50 = 99 نانومتر ، Kd = 98 نانومتر ؛ CDK13: Kd = 4.9 نانومتر)يعمل SR-4835 بالتآزر مع العلاج الكيميائي المدمر للحمض النووي ومثبطات PARP ويؤدي إلى موت خلايا سرطان الثدي الثلاثي السلبي (TNBC)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2387704-62-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death[1].
[1]. Quereda V, et al. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Oct 8. pii: S1535-6108(19)30424-6.
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *